Search Results - "De la Haba‐Rodriguez, Juan"

Nitric oxide-targeted therapy inhibits stemness and increases the efficacy of tamoxifen in estrogen receptor-positive breast cancer cells by López-Sánchez, Laura M., Mena, Rafael, Guil-Luna, Silvia, Mantrana, Ana, Peñarando, Jon, Toledano-Fonseca, Marta, Conde, Francisco, De la Haba-Rodríguez, Juan R., Aranda, Enrique, Rodríguez-Ariza, Antonio

“…Cancer stem cells (CSCs) are involved in the resistance of estrogen (ER)-positive breast tumors against endocrine therapy. On the other hand, nitric oxide (NO)…”
Get full text

Basal VEGF-A and ACE Plasma Levels of Metastatic Colorectal Cancer Patients Have Prognostic Value for First-Line Treatment with Chemotherapy Plus Bevacizumab by Ortiz-Morales, M. José, Toledano-Fonseca, Marta, Mena-Osuna, Rafael, Cano, M. Teresa, Gómez-España, Auxiliadora, Haba-Rodríguez, Juan R. De la, Rodríguez-Ariza, Antonio, Aranda, Enrique

“…The identification of factors that respond to anti-angiogenic therapy would represent a significant advance in the therapeutic management of…”
Get full text

SWATH‐based proteomics reveals processes associated with immune evasion and metastasis in poor prognosis colorectal tumours by López‐Sánchez, Laura M., Jiménez‐Izquierdo, Rafael, Peñarando, Jon, Mena, Rafael, Guil‐Luna, Silvia, Toledano, Marta, Conde, Francisco, Villar, Carlos, Díaz, César, Ortea, Ignacio, De la Haba‐Rodríguez, Juan R., Aranda, Enrique, Rodríguez‐Ariza, Antonio

“…Newly emerged proteomic methodologies, particularly data‐independent acquisition (DIA) analysis–related approaches, would improve current gene expression–based…”
Get full text

Circulating Cell-Free DNA-Based Liquid Biopsy Markers for the Non-Invasive Prognosis and Monitoring of Metastatic Pancreatic Cancer by Toledano-Fonseca, Marta, Cano, M. Teresa, Inga, Elizabeth, Rodríguez-Alonso, Rosa, Gómez-España, M. Auxiliadora, Guil-Luna, Silvia, Mena-Osuna, Rafael, de la Haba-Rodríguez, Juan R., Rodríguez-Ariza, Antonio, Aranda, Enrique

“…Liquid biopsy may assist in the management of cancer patients, which can be particularly applicable in pancreatic ductal adenocarcinoma (PDAC). In this study,…”
Get full text

Clinical significance of glycogen synthase kinase 3 (GSK-3) expression and tumor budding grade in colorectal cancer: Implications for targeted therapy by Guil-Luna, Silvia, Rivas-Crespo, Aurora, Navarrete-Sirvent, Carmen, Mantrana, Ana, Pera, Alejandra, Mena-Osuna, Rafael, Toledano-Fonseca, Marta, García-Ortíz, María Victoria, Villar, Carlos, Sánchez-Montero, Maria Teresa, Krueger, Janna, Medina-Fernández, Francisco Javier, De La Haba-Rodríguez, Juan, Gómez-España, Auxiliadora, Aranda, Enrique, Rudd, Christopher E., Rodríguez-Ariza, Antonio

“…Glycogen synthase kinase 3 (GSK-3) has been proposed as a novel cancer target due to its regulating role in both tumor and immune cells. However, the…”
Get full text

NeuroPredict: study of the predictive value of ABCB1 genetic polymorphisms and associated clinical factors in chronic chemotherapy-induced peripheral neuropathy (CIPN) by Vargas-Aliaga, Alicia, De la Haba, María, Contreras, María José, Morales Estevez, Cristina, Porras, Ignacio, Cano, María Teresa, Pulido, Gema, Gómez, María Auxiliadora, Flores-Paco, Pablo, Juan, De La Haba-Rodriguez, Aranda, Enrique

“…Chemotherapy-induced peripheral neuropathy (CIPN) is a common entity (30%-40%) and can significantly limit the quality of life of patients, especially those…”
Get full text

The TRAR gene classifier to predict response to neoadjuvant therapy in HER2‐positive and ER‐positive breast cancer patients: an explorative analysis from the NeoSphere trial by Triulzi, Tiziana, Bianchini, Giampaolo, Di Cosimo, Serena, Pienkowski, Tadeusz, Im, Young‐Hyuck, Bianchi, Giulia Valeria, Galbardi, Barbara, Dugo, Matteo, De Cecco, Loris, Tseng, Ling‐Ming, Liu, Mei‐Ching, Bermejo, Begoña, Semiglazov, Vladimir, Viale, Giulia, Haba‐Rodriguez, Juan, Oh, Do‐Youn, Poirier, Brigitte, Valagussa, Pinuccia, Gianni, Luca, Tagliabue, Elda

“…As most erb‐b2 receptor tyrosine kinase 2 (HER2)‐positive breast cancer (BC) patients currently receive dual HER2‐targeting added to neoadjuvant chemotherapy,…”
Get full text

CoCl2, a mimic of hypoxia, induces formation of polyploid giant cells with stem characteristics in colon cancer by Lopez-Sánchez, Laura M, Jimenez, Carla, Valverde, Araceli, Hernandez, Vanessa, Peñarando, Jon, Martinez, Antonio, Lopez-Pedrera, Chary, Muñoz-Castañeda, Juan R, De la Haba-Rodríguez, Juan R, Aranda, Enrique, Rodriguez-Ariza, Antonio

“…The induction of polyploidy is considered the reproductive end of cells, but there is evidence that polyploid giant cancer cells (PGCCs) contribute to cell…”
Get full text

5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial by Gianni, Luca, Prof, Pienkowski, Tadeusz, Prof, Im, Young-Hyuck, Prof, Tseng, Ling-Ming, MD, Liu, Mei-Ching, MD, Lluch, Ana, MD, Starosławska, Elżbieta, Prof, de la Haba-Rodriguez, Juan, MD, Im, Seock-Ah, Prof, Pedrini, Jose Luiz, MD, Poirier, Brigitte, MD, Morandi, Paolo, MD, Semiglazov, Vladimir, Prof, Srimuninnimit, Vichien, Prof, Bianchi, Giulia Valeria, MD, Magazzù, Domenico, PhD, McNally, Virginia, PhD, Douthwaite, Hannah, MSc, Ross, Graham, FFPM, Valagussa, Pinuccia, BS

“…Summary Background In the primary analysis of the NeoSphere trial, patients given neoadjuvant pertuzumab, trastuzumab, and docetaxel showed a significantly…”
Get full text

Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial by Gianni, Luca, Dr, Pienkowski, Tadeusz, Prof, Im, Young-Hyuck, Prof, Roman, Laslo, MD, Tseng, Ling-Ming, MD, Liu, Mei-Ching, MD, Lluch, Ana, MD, Staroslawska, Elżbieta, Prof, de la Haba-Rodriguez, Juan, MD, Im, Seock-Ah, Prof, Pedrini, Jose Luiz, MD, Poirier, Brigitte, MD, Morandi, Paolo, MD, Semiglazov, Vladimir, Prof, Srimuninnimit, Vichien, Prof, Bianchi, Giulia, MD, Szado, Tania, PhD, Ratnayake, Jayantha, BSc, Ross, Graham, MD, Valagussa, Pinuccia, BS

“…Summary Background Studies with pertuzumab, a novel anti-HER2 antibody, show improved efficacy when combined with the established HER2-directed antibody…”
Get full text

In-silico drug repurposing study predicts the combination of pirfenidone and melatonin as a promising candidate therapy to reduce SARS-CoV-2 infection progression and respiratory distress caused by cytokine storm by Artigas, Laura, Coma, Mireia, Matos-Filipe, Pedro, Aguirre-Plans, Joaquim, Farrés, Judith, Valls, Raquel, Fernandez-Fuentes, Narcis, de la Haba-Rodriguez, Juan, Olvera, Alex, Barbera, Jose, Morales, Rafael, Oliva, Baldo, Mas, Jose Manuel, Srinivasan, Narayanaswamy

“…From January 2020, COVID-19 is spreading around the world producing serious respiratory symptoms in infected patients that in some cases can be complicated by…”
Get full text

Phase III trial evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for advanced breast cancer: the letrozole/fulvestrant and avastin (LEA) study by Martín, Miguel, Loibl, Sibylle, von Minckwitz, Gunter, Morales, Serafín, Martinez, Noelia, Guerrero, Angel, Anton, Antonio, Aktas, Bahriye, Schoenegg, Winfried, Muñoz, Montserrat, Garcia-Saenz, José Ángel, Gil, Miguel, Ramos, Manuel, Margeli, Mireia, Carrasco, Eva, Liedtke, Cornelia, Wachsmann, Grischa, Mehta, Keyur, De la Haba-Rodriguez, Juan R

“…To test whether combining bevacizumab, an anti-vascular endothelial growth factor treatment, with endocrine therapy (ET) could potentially delay the emergence…”
Get full text

Genetic variants in the renin-angiotensin system predict response to bevacizumab in cancer patients by Moreno-Muñoz, Diana, de la Haba-Rodríguez, Juan R., Conde, Francisco, López-Sánchez, Laura M., Valverde, Araceli, Hernández, Vanessa, Martínez, Antonio, Villar, Carlos, Gómez-España, Auxiliadora, Porras, Ignacio, Rodríguez-Ariza, Antonio, Aranda, Enrique

“…Background Currently, there are no predictive biomarkers for anti‐angiogenic strategies in cancer, but response to anti‐angiogenic drugs is associated with…”
Get full text

Triple-Negative PAM50 Non-Basal Breast Cancer Subtype Predicts Benefit from Extended Adjuvant Capecitabine by Asleh, Karama, Lluch, Ana, Goytain, Angela, Barrios, Carlos, Wang, Xue Q, Torrecillas, Laura, Gao, Dongxia, Ruiz-Borrego, Manuel, Leung, Samuel, Bines, José, Guerrero-Zotano, Ángel, García-Sáenz, Jose Ángel, Cejalvo, Juan Miguel, Herranz, Jesus, Torres, Roberto, Haba-Rodriguez, Juan de la, Ayala, Francisco, Gómez, Henry, Rojo, Federico, Nielsen, Torsten O, Martin, Miguel

“…Predictive biomarkers for capecitabine benefit in triple-negative breast cancer (TNBC) have been recently proposed using samples from phase III clinical…”
Get full text

A new updated prognostic index for patients with brain metastases (BMs) treated with palliative whole brain radiotherapy (WBRT) in the era of precision oncology. METASNCore project by Flores-Paco, Pablo, Vargas-Aliaga, Alicia, Guevara, María Geraldina, Lopera, Ignacio, Ruiz, Lucía Rodríguez, López-Herrero, María, Camús, Juan Adrián, López-González, Javier, Inga-Saavedra, Elizabeth, Montero, Marina, Barneto, Isidoro, Gómez-España, Mª Auxiliadora, Ruiz, Estela, Ruza, Marta, Armenta, Ana, Palacios, Amalia, De La Haba-Rodríguez, Juan R., Aranda, Enrique

“…Introduction Palliative WBRT is the main treatment for multiple BMs. Recent studies report no benefit in survival after WBRT compared to palliative supportive…”
Get full text

The Combination of Neutrophil-Lymphocyte Ratio and Platelet-Lymphocyte Ratio with Liquid Biopsy Biomarkers Improves Prognosis Prediction in Metastatic Pancreatic Cancer by Toledano-Fonseca, Marta, Cano, M Teresa, Inga, Elizabeth, Gómez-España, Auxiliadora, Guil-Luna, Silvia, García-Ortiz, María Victoria, Mena-Osuna, Rafael, De la Haba-Rodriguez, Juan R, Rodríguez-Ariza, Antonio, Aranda, Enrique

“…Pancreatic ductal adenocarcinoma (PDAC) is an aggressive cancer with a highly inflammatory microenvironment and liquid biopsy has emerged as a promising tool…”
Get full text

High Proliferation Predicts Pathological Complete Response to Neoadjuvant Chemotherapy in Early Breast Cancer by Alba, Emilio, Lluch, Ana, Ribelles, Nuria, Anton‐Torres, Antonio, Sanchez‐Rovira, Pedro, Albanell, Joan, Calvo, Lourdes, García‐Asenjo, Jose Antonio Lopez, Palacios, Jose, Chacon, Jose Ignacio, Ruiz, Amparo, De la Haba‐Rodriguez, Juan, Segui‐Palmer, Miguel A., Cirauqui, Beatriz, Margeli, Mireia, Plazaola, Arrate, Barnadas, Agusti, Casas, Maribel, Caballero, Rosalia, Carrasco, Eva, Rojo, Federico

“…Background. In the neoadjuvant setting, changes in the proliferation marker Ki67 are associated with primary endocrine treatment efficacy, but its value as a…”
Get full text

The role of CDK4/6 inhibitors in early breast cancer by Gil-Gil, Miguel, Alba, Emilio, Gavilá, Joaquín, de la Haba-Rodríguez, Juan, Ciruelos, Eva, Tolosa, Pablo, Candini, Daniele, Llombart-Cussac, Antonio

“…The use of cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) has proven to be a successful strategy in the treatment of advanced hormone receptor-positive (HR+)…”
Get full text

Altered S-nitrosothiol homeostasis provides a survival advantage to breast cancer cells in HER2 tumors and reduces their sensitivity to trastuzumab by Cañas, Amanda, López-Sánchez, Laura M., Peñarando, Jon, Valverde, Araceli, Conde, Francisco, Hernández, Vanessa, Fuentes, Elena, López-Pedrera, Chary, de la Haba-Rodríguez, Juan R., Aranda, Enrique, Rodríguez-Ariza, Antonio

“…The monoclonal antibody trastuzumab against HER2/neu, which is overexpressed in 15–20% of breast cancers, has clinical efficacy but many patients do not…”
Get full text

A PAM50-Based Chemoendocrine Score for Hormone Receptor-Positive Breast Cancer with an Intermediate Risk of Relapse by Prat, Aleix, Lluch, Ana, Turnbull, Arran K, Dunbier, Anita K, Calvo, Lourdes, Albanell, Joan, de la Haba-Rodríguez, Juan, Arcusa, Angels, Chacón, José Ignacio, Sánchez-Rovira, Pedro, Plazaola, Arrate, Muñoz, Montserrat, Paré, Laia, Parker, Joel S, Ribelles, Nuria, Jimenez, Begoña, Bin Aiderus, Abdul Aziz, Caballero, Rosalía, Adamo, Barbara, Dowsett, Mitch, Carrasco, Eva, Martín, Miguel, Dixon, J Michael, Perou, Charles M, Alba, Emilio

“…Hormone receptor-positive (HR ) breast cancer is clinically and biologically heterogeneous, and subgroups with different prognostic and treatment sensitivities…”
Get full text